Monthly Archives: May 2020

Technology across the world is improving and innovatingwith time. Over the years, man-managed labor has almost finished from themarket and more and more technological and scientific gadgets are taking placemaking human labor more effective, efficient, and precise.

Medical science has also taken a lot of advantage fromthis scientific advancement therefore, we can say that doctors are making fulluse of science and technology and the world of medicine has evolved quiterapidly.

Orthopedic hospitalshave also seena remarkable transformation over time and the days when a regular orthopedicclinic only comprised of a few tools and a bad. The launch of innovativetechnologies, biologics, and hybrid items into the orthopedic industry isincreasingly growing.

Any of these emerging inventions gain regulatory approvalby showing significant equivalence to the US System of the Food and DrugAdministration (FDA) 510(k).

Surgeons play a key role in the implementation ofemerging technology to patients and will play a leading role in supportinghealthy, efficient, adequate, and cost-effective treatment, particularly forsurgical procedures. Surgeons will track and record the health results andadverse effects of their patients utilizing modern technologies and ensure thatthe new technology works as expected.

Ortho-biologics utilizes the regenerative ability ofcells in the human body. Ortho-biologics are created from compounds naturallypresent in the body which are used to facilitate the recovery of fracturedbones which injured joints, ligaments, and tendons.

These involve bone graft, growth factors, stem cells,platelet-infused plasma, autologous blood, and autologous controlled serum. Themesenchymal stem cells (MSCs) contained in the bone marrow has been shown to besuccessful in the production of the appropriate tissues.

Result in Orthopedic Procedures

Recent advances in this area, including growth factor andstem cell therapies, may contribute to faster recovery. One breakthrough isdrug-free bone grafts, which may be used to cure conditions such as orthopedicsurgery. Clinical trials have demonstrated that growth factors can improve thehealing cycle.

Stem cells will continually self-regenerate and transforminto either form of cell, providing an unmatched source of regenerativemedicine technology. Definitions of musculoskeletal procedures utilizing stemcells are listed below.

Biotechnology firms began utilizing orthopedic stemcells. For starters, BioTime works on stem cell therapies for age-relateddegenerative diseases, IntelliCell BioSciences on adipose-derived stem cellsfor orthopedic conditions, and Bio-Tissues on Ortho-biological treatments forcartilage defects.

Orthopedic procedures using robots are less intrusive anddeliver reproducible accuracy, resulting in shorter hospital stays and quickerrecovery times. The Swiss clinic, La Source, recorded a decline in averagehospitalization from 10 to 6 days with the usage of surgical robots.Nevertheless, this technology is also costly to develop, so solid,evidence-based trials are required to prove that robotic technology contributesto improved outcomes.

The Da Vinci Surgical Method became the first U.S. Food andDrug Administration (FDA)-an authorized robotic surgery program in 2000. Morebusinesses are investing in this technology to enhance navigation duringservice or to receive 3-D scans that aid in the design of custom joints.

Organizations that are interested, in robotics areinclined towards the following technological masterpieces:

Several modern surgical techniques are enhancing theresults. These involve motion-preservation methods, minimally intrusive surgery,tissue-guided surgery, and cement-free joint repair.

Motion recovery strategies require partial or completedisk removal and the usage of active stability systems and interspinous spacersthat do not impair versatility.

Minimally intrusive procedures involve the use ofendoscopes, tubular retractors, and computer-aided guidance devices, allowingan incision of just 2 cm instead of 12 cm in conventional therapies. Minimallyinvasive treatments are gaining popularity in joint and hip replacement and spinalsurgery.

Smart devices provide built-in sensors to offer real-timetracking and post-operative evaluation details to surgeons for better patientsafety across the clinical process. Such implants have the ability to minimizeperiprosthetic infection, which is an increasing orthopedic issue.Sensor-enabled innovations also presented health care professionals with arange of innovative, cost-effective goods.

Companies working in this field include:

3-D orthopedic printing is gaining traction in themanufacture of personalized braces, surgical equipment, and orthotics from arange of materials. 3-D printing technology cuts operating times, saves energy,increases the long-term reliability of the implant, and enhances the healtheffects of surgical procedures. 3-D printing technologies of orthopedics areinclusive of:

Companies investing in 3-D Orthopedic Printing

Medical science has taken a huge turn with the introduction of technology. The orthopedic industry has also transformed to a huge extent making sure that the specialists and surgeons are able to treat and operate on their patients without any hassle. Almost all the orthopedic hospitals are equipped with high-end gadgets and tools to assist the doctor.

Even though the technology has evolved greatly since thefield of medicine was invented, it is important to understand that this is justa beginning and there are many more things to come in the future.

Read more from the original source:
The Latest Technological Innovations in Orthopedic Surgery 2020 Technology - IMC Grupo

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte Inc., a biotech company dedicated to improving the lives of patients with rare degenerative retinal diseases, today announced it has entered into a licensing agreement with Santen Pharmaceutical to develop and commercialize its first-in-class, investigational therapy, jCell, outside the U.S., in regions including Europe, Asia and Japan.

Under the terms of the licensing agreement, jCyte will receive $50 million in upfront cash, $12 million in a convertible note offering, and $190 million in clinical and sales milestones based on regulatory approval and initial sales in Europe, Asia and Japan. The total deal is valued at up to $252 million. jCyte is also entitled to receive tiered, double-digit royalty payments on net sales of jCell therapy once commercialized outside the U.S.

We are thrilled to partner with Santen, a global market-leader in ophthalmology. By leveraging Santens large, existing global commercial and medical infrastructure in ophthalmology, as well as its commitment to commercializing cell and gene therapies, we help ensure that more patients with retinitis pigmentosa who live outside the U.S. will have access to this technology, said Paul Bresge, Chief Executive Officer, jCyte, Inc. We intend to use the proceeds from this transaction to continue development of our lead investigational therapy jCell, to improve the lives of patients with retinitis pigmentosa, as well as other degenerative retinal diseases.

jCell is a first-in-class investigational treatment for retinitis pigmentosa, an inherited retinal disease. The treatment is a minimally-invasive intravitreal injection, which can be performed in an ophthalmologists office with topical anesthetic. The entire procedure takes less than 30 minutes. The principal mechanism of action is the release of neurotrophic factors that may rescue diseased retinal cells. jCell therapy aims to preserve vision by intervening in the disease at a time when host photoreceptors can be protected and potentially reactivated. jCell has been developed with support from the California Institute for Regenerative Medicine (CIRM), which has funded previous preclinical development and ongoing clinical studies.

In the United States, the evaluable portion of a Phase 2b clinical trial of jCell for the treatment of retinitis pigmentosa has been completed, and the crossover portion continues. jCell therapy has been administered in over 100 patients. The U.S. Food and Drug Administration (FDA) has granted jCyte Regenerative Medicine Advanced Therapy (RMAT) designation based on early clinical data, making jCell potentially eligible for BLA priority review. In addition to RMAT, jCell has received Orphan Drug designation from the FDA and the European Medicines Agency (EMA).

About Retinitis Pigmentosa (RP)

Retinitis pigmentosa is a rare, genetic condition that progressively destroys the rod and cone photoreceptors in the retina. It often strikes people in their teens, with many patients rendered legally blind by middle age. Worldwide, an estimated 1.9 million people suffer from the disease, including approximately 100,000 people in the U.S., making it the leading cause of inheritable blindness.

About jCyte, Inc.

jCyte, Inc. is a clinical-stage biotech company focused on developing jCell therapy for retinitis pigmentosa (RP) and other degenerative retinal disorders. jCell is a first-in-class investigational treatment for retinitis pigmentosa, an inherited retinal disease. The treatment is minimally-invasive and given as an intravitreal injection. There are currently no FDA approved therapies for RP. The company is pioneering a new era of regenerative therapies to treat patients with unmet medical need. For more information, visit http://www.jcyte.com.

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santens website (www.santen.com).

Read more here:
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical -...

-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)-

-First Ever Study in DMD that Correlates Stabilization in Cardiac Function with a Reduction in a Biomarker of Cell Damage-

-Company Planning to Meet with FDA to Discuss Pathway to Approval-

-To Host Conference Call and Webcast Today at 8AM ET-

LOS ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Capricor) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today positive top-line 12-month results of the HOPE-2 clinical trial using CAP-1002 to treat patients in advanced stages of Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. Boys and young men typically lose their ability to walk in their teens and generally die of cardiac or respiratory complications by the 3rd decade of life. The datashowed improvements in upper limb, cardiac and respiratory function with p-values less than p=0.05 in multiple measures.

The 12-month data from HOPE-2 showed statistically meaningful improvements in the PUL 2.0 in CAP-1002 treated patients (p=0.05) with a mean change of 2.4 points over placebo patients. With the exception of steroids, preservation of function in DMD is uncommon. The placebo patients declined consistent with natural history, but in the treated group, most patients were stable or improved throughout the one-year treatment period.

The performance of the upper limb (PUL) is a clinically validated measure that evaluates upper limb (shoulder, arm, hand) strength in patients who are generally non-ambulant. Retention of upper limb function is important for self-care and preservation of human dignity and has become a focus for physicians and advocates to find treatments to help these later stage patients. The FDA has suggested the use of the updated PUL 2.0 version as the primary efficacy endpoint in support of a Biologics License Application (BLA).

Craig McDonald, M.D., the national principal investigator for the HOPE-2 clinical trial and UC Davis professor and chair of the Department of Physical Medicine and Rehabilitation commented, I am incredibly pleased with the outcome of the HOPE-2 trial which demonstrated clinically relevant benefits of CAP-1002 which resulted in measurable improvements in upper limb, cardiac and respiratory function. This is the first clinical trial which shows benefit to patients in advanced stages of DMD for which treatment options are limited.

The data also showed global improvements in cardiac function as measured by ejection fraction (p=0.004) and indexed volumes (LVESV, p=0.01, LVEDV p=0.07). These are surrogate measures of cardiac function and are considered the gold standard in terms of relevance to long term outcomes. Remarkably, there is also a reduction in the biomarker CK-MB, an enzyme that is only released when there is cardiac muscle cell damage. In normal human subjects, there is typically no CK-MB measurable in the blood. It is well accepted that continuous muscle cell damage in DMD leads to pathologically high enzyme levels associated with cardiac muscle cell loss. HOPE-2 demonstrated a reduction in CK-MB levels as compared to placebo (p=0.006). This is the first ever study in DMD that correlates cardiac functional stabilization with reduction of a biomarker of cell damage.

Linda Marbn, president and CEO of Capricor said, To date, there are no therapies to treat the cardiomyopathy associated with DMD. Based on the statistically and clinically meaningful improvements in these and other measures of skeletal, cardiac and respiratory performance, we have requested an End-of-Phase 2 meeting with FDA to discuss next steps and a pathway to approval of a Biologics License Application for CAP-1002 in DMD.

Phase II HOPE-2 Study Design

HOPE-2 is a randomized, double-blind, placebo-controlled, Phase II clinical trial of the Companys lead investigational therapy, CAP-1002, in boys and young men who are in advanced stages of DMD. Study patients were treated via intravenous delivery with either CAP-1002 (150 million cells per infusion) or placebo every 3 months. Data from a total of 20 patients was analyzed (12 placebo and 8 treated) at the 12-month time-point in the intent to treat (ITT) population. Approximately 80% of the patients were non-ambulant and all patients were on a stable regimen of steroids. Demographic and baseline characteristics were similar between the two treatment groups.

Study Results

Top-Line Efficacy Data:

Mean Change from baseline to 12 months (standard deviation) shown.ITT (intent to treat) population shown P-values are nominal values unadjusted for multiple testing Mixed model repeated measures analysis

Dr. Marban continued, We are delighted with the final data from HOPE-2. It has met our expectations in terms of clinical meaningfulness in this population of patients where treatment options are extremely limited. In HOPE-2, CAP-1002 was delivered by intravenous infusions given quarterly. The data suggests that CAP-1002 could delay the progression of DMD. We are excited to share this data with FDA and discuss next steps towards commercialization. We have had tremendous support from the DMD advocacy community and we are grateful to the patients and families who participated in this study so that we could reveal the impact of CAP-1002 in treating DMD.

Safety Update

CAP-1002 was generally safe and well tolerated throughout the study. With the exception of hypersensitivity reactions which were mitigated with a common pre-medication regimen, no safety signals were identified in the HOPE-2 trial.

The FDA has granted Capricors CAP-1002 RMAT and Orphan Drug Designation, and the FDA has also granted a Rare Pediatric Disease Designation to CAP-1002 for DMD. The Rare Pediatric Disease Designation, as well as the Orphan Drug Designation previously granted, covers the broad treatment of DMD. If Capricor were to receive market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher. This is the second clinical trial investigating CAP-1002 showing similar results in DMD. Capricor completed the HOPE-Duchenne (Phase I/II) trial published in Neurology, the medical journal of the American Academy of Neurology in 2019.

The Company has initiated a technology transfer with a leading global CMO to prepare for commercial manufacturing of CAP-1002.

Conference Call and Webcast Details

Capricor will host a conference call and webcast with slides today, May 13, 2020, at 8:00 a.m. ET to discuss the top-line results of the HOPE-2 study. To participate in the conference call, please dial 855-327-6838 (domestic) or 604-235-2082 (international) and reference the access code: 10009621.

To participate via a webcast, please visit: http://public.viavid.com/index.php?id=139843 to view the slides. The webcast will be archived for approximately 30 days and will be available at http://capricor.com/news/events/.

Financial Update for the First Quarter of 2020

The Company reported a net loss of approximately $2.1 million, or $0.30 per share, for the first quarter of 2020, compared to a net loss of approximately $2.5 million, or $0.75 per share, for the first quarter of 2019.

As of March 31, 2020, the Companys cash, cash equivalents and marketable securities totaled approximately $13.2 million, compared to approximately $9.9 million on December 31, 2019. As of May 12, 2020, the Company has 12,464,006 shares issued and outstanding.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment and prevention of diseases. Capricors lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine. For more information,visit http://www.capricor.com and follow the Company on Facebook, Instagram and Twitter.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a devastating genetic disorder that causes muscle degeneration and leads to death, generally before the age of 30, most commonly from heart failure. It occurs in one in every 3,600 live male births across all races, cultures and countries. Duchenne muscular dystrophy afflicts approximately 200,000 boys and young men around the world. Treatment options are limited, and there is no cure.

About CAP-1002

CAP-1002 consists of allogeneic off-the-shelf cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune systems activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. CDCs have been the subject of over 100 peer-reviewed scientific publications and administered to approximately 150 human subjects across several clinical trials.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricors exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Media Contact:Caitlin KasunichKCSA Strategic Communicationsckasunich@kcsa.com212.896.1241

Investor Contact:Joyce Allaire LifeSci Advisors, LLCjallaire@lifesciadvisors.com617.435.6602

Company Contact:AJ Bergmann, Chief Financial Officerabergmann@capricor.com310.358.3200

Follow this link:
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002...

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook.

Extracellular Matrix Market accounted to US$ 24.30 Mn in 2018 and is expected to grow at a CAGR of 8.2% during the forecast period 2019 2027, to account to US$ 47.46Mn by 2027.

The growth is driven by that countries such as China, Japan, and India which are engaged in conducting several studies. For instance, Australia is also involved in the several studies and also it has held various conferences for the tissue engineering and other application of the extracellular matrix.

Download a Sample Report Explore further @https://www.theinsightpartners.com/sample/TIPRE00004925

Top Dominating Key Players:

The potential of regenerative medicine that facilitates tissue regeneration in the affected area reduced the requirement of tissue transplant. The extracellular matrix is derived from a readily available tissue source, it can stimulate the growth of tissue in vivo with minimal inflammation, and it is available off the shelf. These advantages of the extracellular matrix enables in the ideal soft tissue replacement treatment procedures to repair contour defects. Therefore, there is increase in the vascular reconstruction or the plastic surgeries are anticipated to grow the extracellular matrix during the forecast period.

The studies for the molecular cell biology of extracellular matrix (ECM) are being conducted across the world. The cell adhesion molecules (CAMs), other properties and advantages of the extracellular matrix are turning out to be beneficial area of discovery with several interesting factors for disease and disorders in animals and humans. These advantages are also include treating of some cancers such as breast cancer, pancreatic cancer, liver cancer and colon cancer.

The globalextracellular matrix marketby raw material segments was led by porcine segment. In 2018, the porcine segment held a largest market share of 41.09% of the extracellular matrix market, by raw material. However, the bovine segment is expected to be the fastest growing segments of the market in 2027 owing to more beneficial properties to treat various conditions which is expected to become the major factor for the growth of the extracellular matrix market.

Request for Buy Report @https://www.theinsightpartners.com/buy/TIPRE00004925

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:[emailprotected]

Continue reading here:
Extracellular Matrix Market to Reap Over US$ 47.46Mn in Revenues by End of 2027 - Cole of Duty

ISPE drives industry-wide clarity of new regulations and guidance, advising on potential impact and facilitating practical solutions, seeking harmonization of regulatory expectations where desired and possible.

NORTH BETHESDA, Md. (PRWEB) May 13, 2020

The International Society for Pharmaceutical Engineering (ISPE) announced featured presenters representing the Food and Drug Administration (FDA) at the 2020 ISPE Biopharmaceutical Manufacturing Virtual Conference. Taking place 12 June 2020, this first of its kind fully interactive digital event features timely and topical presentations and panel discussions from 40+ global experts representing FDA, GSK, Kite Pharma, Novartis, Roche, and more.

Featured FDA presenters will provide updates on regulatory expectations, considerations, and perspectives on biotechnology and biological products.

ISPE drives industry-wide clarity of new regulations and guidance, advising on potential impact and facilitating practical solutions, seeking harmonization of regulatory expectations where desired and possible, said Tim Howard, PE, CPIP, President & CEO, ISPE. It's vital that the biopharmaceutical industry pay close attention to what the regulators have to say and that we continue to develop constructive relationships.

FDA Presenters:

Wilson Bryan, MD, Director, Office of Tissues and Advanced Therapies, FDA/CBERDr. Bryans keynote presentation will provide insights into current developments in regenerative medicine, future trends, and challenges.

Patricia Hughes, PhD, Branch Chief, Division of Microbiology Assessment, FDA/CDERDr. Hughes will share regulatory considerations of innovations in sterile manufacturing and will also join the closing Fireside Chat.

Richard Friedman, Deputy Director, Science & Regulatory Policy, FDA/CDERFriedman will provide updates on sterile products and change management.

Raj Puri, MD, PhD, Director, Division of Cellular & Gene Therapies, FDA/CBERDr. Puri will participate in the closing Fireside Chat featuring global regulatory and industry leaders who are working to frame the strategy for the era ahead.

In addition to regulatory insights, industry experts will share their knowledge and lessons learned on critical topics, including:

To explore the educational agenda and to register, please visit ISPE.org/Bio20.

About ISPEThe International Society for Pharmaceutical Engineering (ISPE) is the worlds largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.

For more information, contact: Amy HenryMarketing Communications ManagerInternational Society for Pharmaceutical Engineering (ISPE)Email: ahenry@ispe.org ISPE.org

Share article on social media or email:

Continued here:
FDA Leaders to Speak at the 2020 ISPE Biopharmaceutical Manufacturing Virtual Conference - PR Web

Los Angeles, United State- The global Human Embryonic Stem Cells (HESC) market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Human Embryonic Stem Cells (HESC) market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Human Embryonic Stem Cells (HESC) Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Human Embryonic Stem Cells (HESC) market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Human Embryonic Stem Cells (HESC) market.

Leading players of the global Human Embryonic Stem Cells (HESC) market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Human Embryonic Stem Cells (HESC) market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Human Embryonic Stem Cells (HESC) market. It also provides useful recommendations for new as well as established players of the global Human Embryonic Stem Cells (HESC) market.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :https://www.qyresearch.com/sample-form/form/1749373/covid-19-impact-on-human-embryonic-stem-cells-hesc-market

Human Embryonic Stem Cells (HESC) Market Leading Players

ESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolife, etc.

Human Embryonic Stem Cells (HESC) Segmentation by Product

, Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells

Human Embryonic Stem Cells (HESC) Segmentation by Application

, Research, Clinical Trials, Others

Report Objectives

Analyzing the size of the global Human Embryonic Stem Cells (HESC) market on the basis of value and volume.

Accurately calculating the market shares, consumption, and other vital factors of different segments of the global Human Embryonic Stem Cells (HESC) market.

Exploring the key dynamics of the global Human Embryonic Stem Cells (HESC) market.

Highlighting important trends of the global Human Embryonic Stem Cells (HESC) market in terms of production, revenue, and sales.

Deeply profiling top players of the global Human Embryonic Stem Cells (HESC) market and showing how they compete in the industry.

Studying manufacturing processes and costs, product pricing, and various trends related to them.

Showing the performance of different regions and countries in the global Human Embryonic Stem Cells (HESC) market.

Forecasting the market size and share of all segments, regions, and the global market.

Get Full report in your inbox within 24 hours at USD (3250) :https://www.qyresearch.com/settlement/pre/08101371beb1ead901ab2ea442a36625,0,1,covid-19-impact-on-human-embryonic-stem-cells-hesc-market

Table of Contents.

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Human Embryonic Stem Cells (HESC) Industry1.7 COVID-19 Impact: Human Embryonic Stem Cells (HESC) Market Trends 2 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size Analysis2.1 Human Embryonic Stem Cells (HESC) Business Impact Assessment COVID-192.1.1 Global Human Embryonic Stem Cells (HESC) Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.1.2 Global Human Embryonic Stem Cells (HESC) Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size by Manufacturers, 2019 VS 20203.2 Global Human Embryonic Stem Cells (HESC) Factory Price by Manufacturers3.3 Location of Key Manufacturers Human Embryonic Stem Cells (HESC) Manufacturing Factories and Area Served3.4 Date of Key Manufacturers Enter into Human Embryonic Stem Cells (HESC) Market3.5 Key Manufacturers Human Embryonic Stem Cells (HESC) Product Offered3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Human Embryonic Stem Cells (HESC) Segments, By Type4.1 Introduction1.4.1 Totipotent Stem Cells1.4.2 Pluripotent Stem Cells1.4.3 Unipotent Stem Cells4.2 By Type, Global Human Embryonic Stem Cells (HESC) Market Size, 2019-20214.2.1 By Type, Global Human Embryonic Stem Cells (HESC) Market Size by Type, 2020-20214.2.2 By Type, Global Human Embryonic Stem Cells (HESC) Price, 2020-2021 5 Impact of Covid-19 on Human Embryonic Stem Cells (HESC) Segments, By Application5.1 Overview5.5.1 Research5.5.2 Clinical Trials5.5.3 Others5.2 By Application, Global Human Embryonic Stem Cells (HESC) Market Size, 2019-20215.2.1 By Application, Global Human Embryonic Stem Cells (HESC) Market Size by Application, 2019-20215.2.2 By Application, Global Human Embryonic Stem Cells (HESC) Price, 2020-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 ESI BIO7.1.1 ESI BIO Business Overview7.1.2 ESI BIO Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.1.3 ESI BIO Human Embryonic Stem Cells (HESC) Product Introduction7.1.4 ESI BIO Response to COVID-19 and Related Developments7.2 Thermo Fisher7.2.1 Thermo Fisher Business Overview7.2.2 Thermo Fisher Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.2.3 Thermo Fisher Human Embryonic Stem Cells (HESC) Product Introduction7.2.4 Thermo Fisher Response to COVID-19 and Related Developments7.3 BioTime7.3.1 BioTime Business Overview7.3.2 BioTime Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.3.3 BioTime Human Embryonic Stem Cells (HESC) Product Introduction7.3.4 BioTime Response to COVID-19 and Related Developments7.4 MilliporeSigma7.4.1 MilliporeSigma Business Overview7.4.2 MilliporeSigma Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.4.3 MilliporeSigma Human Embryonic Stem Cells (HESC) Product Introduction7.4.4 MilliporeSigma Response to COVID-19 and Related Developments7.5 BD Biosciences7.5.1 BD Biosciences Business Overview7.5.2 BD Biosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.5.3 BD Biosciences Human Embryonic Stem Cells (HESC) Product Introduction7.5.4 BD Biosciences Response to COVID-19 and Related Developments7.6 Astellas Institute of Regenerative Medicine7.6.1 Astellas Institute of Regenerative Medicine Business Overview7.6.2 Astellas Institute of Regenerative Medicine Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.6.3 Astellas Institute of Regenerative Medicine Human Embryonic Stem Cells (HESC) Product Introduction7.6.4 Astellas Institute of Regenerative Medicine Response to COVID-19 and Related Developments7.7 Asterias Biotherapeutics7.7.1 Asterias Biotherapeutics Business Overview7.7.2 Asterias Biotherapeutics Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.7.3 Asterias Biotherapeutics Human Embryonic Stem Cells (HESC) Product Introduction7.7.4 Asterias Biotherapeutics Response to COVID-19 and Related Developments7.8 Cell Cure Neurosciences7.8.1 Cell Cure Neurosciences Business Overview7.8.2 Cell Cure Neurosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.8.3 Cell Cure Neurosciences Human Embryonic Stem Cells (HESC) Product Introduction7.8.4 Cell Cure Neurosciences Response to COVID-19 and Related Developments7.9 PerkinElmer7.9.1 PerkinElmer Business Overview7.9.2 PerkinElmer Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.9.3 PerkinElmer Human Embryonic Stem Cells (HESC) Product Introduction7.9.4 PerkinElmer Response to COVID-19 and Related Developments7.10 Takara Bio7.10.1 Takara Bio Business Overview7.10.2 Takara Bio Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.10.3 Takara Bio Human Embryonic Stem Cells (HESC) Product Introduction7.10.4 Takara Bio Response to COVID-19 and Related Developments7.11 Cellular Dynamics International7.11.1 Cellular Dynamics International Business Overview7.11.2 Cellular Dynamics International Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.11.3 Cellular Dynamics International Human Embryonic Stem Cells (HESC) Product Introduction7.11.4 Cellular Dynamics International Response to COVID-19 and Related Developments7.12 Reliance Life Sciences7.12.1 Reliance Life Sciences Business Overview7.12.2 Reliance Life Sciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.12.3 Reliance Life Sciences Human Embryonic Stem Cells (HESC) Product Introduction7.12.4 Reliance Life Sciences Response to COVID-19 and Related Developments7.13 Research & Diagnostics Systems7.13.1 Research & Diagnostics Systems Business Overview7.13.2 Research & Diagnostics Systems Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.13.3 Research & Diagnostics Systems Human Embryonic Stem Cells (HESC) Product Introduction7.13.4 Research & Diagnostics Systems Response to COVID-19 and Related Developments7.14 SABiosciences7.14.1 SABiosciences Business Overview7.14.2 SABiosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.14.3 SABiosciences Human Embryonic Stem Cells (HESC) Product Introduction7.14.4 SABiosciences Response to COVID-19 and Related Developments7.15 STEMCELL Technologies7.15.1 STEMCELL Technologies Business Overview7.15.2 STEMCELL Technologies Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.15.3 STEMCELL Technologies Human Embryonic Stem Cells (HESC) Product Introduction7.15.4 STEMCELL Technologies Response to COVID-19 and Related Developments7.16 Stemina Biomarker Discovery7.16.1 Stemina Biomarker Discovery Business Overview7.16.2 Stemina Biomarker Discovery Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.16.3 Stemina Biomarker Discovery Human Embryonic Stem Cells (HESC) Product Introduction7.16.4 Stemina Biomarker Discovery Response to COVID-19 and Related Developments7.17 Takara Bio7.17.1 Takara Bio Business Overview7.17.2 Takara Bio Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.17.3 Takara Bio Human Embryonic Stem Cells (HESC) Product Introduction7.17.4 Takara Bio Response to COVID-19 and Related Developments7.18 TATAA Biocenter7.18.1 TATAA Biocenter Business Overview7.18.2 TATAA Biocenter Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.18.3 TATAA Biocenter Human Embryonic Stem Cells (HESC) Product Introduction7.18.4 TATAA Biocenter Response to COVID-19 and Related Developments7.19 UK Stem Cell Bank7.19.1 UK Stem Cell Bank Business Overview7.19.2 UK Stem Cell Bank Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.19.3 UK Stem Cell Bank Human Embryonic Stem Cells (HESC) Product Introduction7.19.4 UK Stem Cell Bank Response to COVID-19 and Related Developments7.20 ViaCyte7.20.1 ViaCyte Business Overview7.20.2 ViaCyte Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.20.3 ViaCyte Human Embryonic Stem Cells (HESC) Product Introduction7.20.4 ViaCyte Response to COVID-19 and Related Developments7.21 Vitrolife7.21.1 Vitrolife Business Overview7.21.2 Vitrolife Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 20207.21.3 Vitrolife Human Embryonic Stem Cells (HESC) Product Introduction7.21.4 Vitrolife Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis8.1 Human Embryonic Stem Cells (HESC) Supply Chain Analysis8.1.1 Human Embryonic Stem Cells (HESC) Supply Chain Analysis8.1.2 Covid-19 Impact on Human Embryonic Stem Cells (HESC) Supply Chain8.2 Distribution Channels Analysis8.2.1 Human Embryonic Stem Cells (HESC) Distribution Channels8.2.2 Covid-19 Impact on Human Embryonic Stem Cells (HESC) Distribution Channels8.2.3 Human Embryonic Stem Cells (HESC) Distributors8.3 Human Embryonic Stem Cells (HESC) Customers 9 Key Findings 10 Appendix10.1 About Us10.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read the original post:
Human Embryonic Stem Cells (HESC) Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key...